R&D News | pharmaphorum

News

Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.

News

After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.

News

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

News

Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.

News

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.